Glanzmann Thrombasthenia Market

Glanzmann Thrombasthenia Market Overview

Glanzmann Thrombasthenia is a rare genetic disorder. It is blood clotting disorder which is characterized by compromised functioning of the specialized blood cells (platelets). Platelets are crucial for proper blood clotting. Glanzmann Thrombasthenia disorder has normal number of platelets in the blood with abnormal function of the platelets.

The symptoms of glanzmann thrombasthenia include profuse bleeding, especially after any surgical procedure, susceptibility of easy bruising, intermittent gastrointestinal bleeding, bleeding from gums, nose bleeding and purple or red visibly large patches on the skin caused by internal bleeding under the skin.

Women suffering from glanzmann thrombasthenia may suffer from excessive menstrual bleeding, disproportionate bleeding during childbirth, irregular uterine bleeding. The symptoms of glanzmann thrombasthenia vary greatly from mild bruising to severe haemorrhages making it even life-threatening.

The severity of COVID-19 affecting different population lies in the different genetic build-up of these populations. Scientists all over the world are trying to understand this correlation. Since, it is a novel virus and not much information is available to the scientific community, it is quite unknown how it can affect the people suffering from rare genetic diseases like glanzmann thrombasthenia.

Glanzmann Thrombasthenia Market: Drivers and Restraints

The major push factors for the global market of glanzmann thrombasthenia treatment are increasing healthcare expenditure by the various governments worldwide coupled with growing awareness in the general public about rare genetic blood clotting disorders. Another factor could be there is increased number of diagnosed population worldwide suffering from some or the other blood clotting disorder.

The increasing sophistication of healthcare network around the globe in terms of new collaborations between governments of various countries, research institutes and academia will generate a new momentum for the global market of glanzmann thrombasthenia treatment.

However, there are some pull factors also which would act as roadblocks in the development of glanzmann thrombasthenia market. First among them could be high cost of treatment required for rare genetic diseases in general and blood clotting disorders in particular.

Lack of adequate healthcare infrastructure and facilities for early diagnosis and treatment is the other factor which could hamper the growth of global market of glanzmann thrombasthenia treatment. Lastly, often the diagnosis of glanzmann thrombasthenia go unnoticed, resulting in no treatment, further hindering the market.

Glanzmann Thrombasthenia Market: Overview

Based on drug class, the recombinant activated factor VII segment in the global glanzmann thrombasthenia market seems to register promising growth based on the fact that the treatment is successful in stopping bleeding in almost 90% of the cases of glanzmann thrombasthenia.

Based on the distribution channel, hospital pharmacies segment in the global glanzmann thrombasthenia market is estimated to grow fastest owing to the treatment of rare genetic disease under the guidance of professional medical expert.

Glanzmann Thrombasthenia Market: Region-wise Outlook

The global glanzmann thrombasthenia market will witness a different pattern as compared to other market patterns in terms of region wise dominance. Middle East can be estimated to be the lucrative market for glanzmann thrombasthenia as most cases of glanzmann thrombasthenia are observed in the Middle East region and some particular regions of Europe.

Countries like Iran, Israel, Saudi Arabia, Jordan, Iraq, Palestine have majority of cases owing to the fact of consanguinity being a common feature of these societies. Pockets of Asia, like Southern India have also registered some cases of glanzmann thrombasthenia.

European Countries like France and Romania can be estimated to be other emergent market owing to some incidences of glanzmann thrombasthenia. North America, however, can still be estimated to be an important market for the global glanzmann thrombasthenia market since the pharmaceutical industry there has the skills and resources to spur the growth.

Glanzmann Thrombasthenia Treatment Market: Key Players

The key players functioning the global market for glanzmann thrombasthenia are

• Novo Nordisk
• Alnylam Pharmaceuticals
• Shire (Takeda)
• Biogen
• Bioverativ (Sanofi)
• Bayer
• CSL Behring
• Grifols
• Bristol-Myers Squibb and Pfizer.

The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to market segments such as geographies, application, and industry.

The report covers exhaust analysis on

• Market Segments
• Market Dynamics
• Market Size
• Supply & Demand
• Current Trends/Issues/Challenges
• Competition & Companies involved
• Indication
• Value Chain

Regional analysis includes

• North America (U.S., Canada)
• Latin America (Mexico. Brazil)
• Europe (Germany, U.K, France, Italy, Spain)
• South Asia (India, ASEAN Countries)
• East Asia (Japan, China & South Korea)
• Oceania (Australia & New Zealand)
• Middle East and Africa (GCC Countries, South Africa, Northern Africa)

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain.The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

Glanzmann Thrombasthenia Market: Segmentation

The global market of glanzmann thrombasthenia is segmented based on the drug class, route of administration, distribution channel and region.

Drug Class:

• Platelet Transfusion
• Recombinant Activated Factor VII
• Antifibrinolytics
• Fibrin Sealants
• Thrombin
• Desmopressin

Route of Administration:

• Oral
• Topical
• Injectable

Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Drug Stores
• Online Pharmacies